Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In Vitro Through an AT2-B2 Receptor Pathway by Munk, V C et al.








Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In
Vitro Through an AT2-B2 Receptor Pathway
Munk, V C; Sanchez de Miguel, L; Petrimpol, M; Butz, N; Banfi, A; Eriksson, U; Hein, L; Humar, R;
Battegay, E J
DOI: 10.1161/HYPERTENSIONAHA.106.080242
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-78571
Originally published at:
Munk, V C; Sanchez de Miguel, L; Petrimpol, M; Butz, N; Banfi, A; Eriksson, U; Hein, L; Humar, R;
Battegay, E J (2007). Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In Vitro
Through an AT2-B2 Receptor Pathway. Hypertension, 49(5):1178-1185. DOI: 10.1161/HYPERTEN-
SIONAHA.106.080242
ISSN: 1524-4563 
Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 0194-911X. Online
72514
Hypertension is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX
DOI: 10.1161/HYPERTENSIONAHA.106.080242 
 published online Mar 5, 2007; Hypertension
Andrea Banfi, Urs Eriksson, Lutz Hein, Rok Humar and Edouard J. Battegay 
Veronica C. Munk, Lourdes Sanchez de Miguel, Marco Petrimpol, Nicole Butz,
 -B2 Receptor Pathway2Through an AT
Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In Vitro
 http://hyper.ahajournals.org
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/static/html/reprints.html
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
Street, Baltimore, MD 21202-2436. Phone 410-5280-4050. Fax: 410-528-8550. Email: 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, 351 West Camden
  
 http://hyper.ahajournals.org/subsriptions/
Subscriptions: Information about subscribing to Hypertension is online at 
 at Medical Library on March 5, 2007 hyper.ahajournals.orgDownloaded from 
Angiotensin II Induces Angiogenesis in the Hypoxic Adult
Mouse Heart In Vitro Through an AT2–B2
Receptor Pathway
Veronica C. Munk, Lourdes Sanchez de Miguel, Marco Petrimpol, Nicole Butz, Andrea Banfi,
Urs Eriksson, Lutz Hein, Rok Humar, Edouard J. Battegay
Abstract—Angiotensin II is a vasoactive peptide that may affect vascularization of the ischemic heart via angiogenesis. In
this study we aimed at studying the mechanisms underlying the angiogenic effects of angiotensin II under hypoxia in
the mouse heart in vitro. Endothelial sprout formation from pieces of mouse hearts was assessed under normoxia (21%
O2) and hypoxia (1% O2) during a 7-day period of in vitro culture. Only under hypoxia did angiotensin II
dose-dependently induce endothelial sprout formation, peaking at 107 mol/L of angiotensin II. Angiotensin II type 1
(AT1) receptor blockade by losartan did not affect angiotensin II–induced sprouting in wild-type mice. Conversely, the
angiotensin II type 2 (AT2) receptor antagonist PD 123319 blocked this response. In hearts from AT1/ mice,
angiotensin II–elicited sprouting was preserved but blocked again by AT2 receptor antagonism. In contrast, no
angiotensin II–induced sprouting was found in preparations from hearts of AT2/ mice. Angiotensin II–mediated
angiogenesis was also abolished by a specific inhibitor of the B2 kinin receptor in both wild-type and AT1/ mice.
Furthermore, angiotensin II failed to induce endothelial sprout formation in hearts from B2/ mice. Finally, NO
inhibition completely blunted sprouting in hearts from wild-type mice, whereas NO donors could restore sprouting in
AT2/ and B2/ hearts. This in vitro study suggests the obligatory role of hypoxia in the angiogenic effect of
angiotensin II in the mouse heart via the AT2 receptor through a mechanism that involves bradykinin, its B2 receptor,
and NO as a downstream effector. (Hypertension. 2007;49:1-8.)
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Ischemic heart disease and left ventricular hypertrophy arecharacterized by impaired cardiac function caused by, among
others, inadequate blood supply to the myocardium. In order to
relieve this condition, blood flow to the myocardium needs to be
restored by remodeling of pre-existing unused collateral blood
vessels (arteriogenesis) and by the growth of new microvessels
(angiogenesis). This process may also prevent the death and
promote regeneration of damaged myocardial tissue.
Angiogenic stimuli are generated by hypoxia through activa-
tion of endothelial cell signaling1 and gene transcription of key
angiogenic molecules, such as vascular endothelial growth
factor (VEGF).2 In mice, activation of pre-existing collateral
vascularization that restores blood flow to the acutely ischemic
heart was shown to be induced by angiotensin II (Ang II),3 a key
regulator of blood pressure and the main effector of the renin–
angiotensin-aldosterone system.4 During ischemia or cancer,
Ang II was shown to induce angiogenesis.5 Two major subtypes
of Ang II receptors are expressed in the myocardium,6 Ang II
type 1 (AT1) and Ang II type 2 (AT2) receptors.7,8 Most of the
Ang II cardiovascular effects, for example, vasoconstriction, are
attributed to AT1.9 AT1 is an ubiquitous receptor that presents 2
subtypes in rodents of a high homology (AT1a and AT1b).10 On
the other hand, the AT2 receptor is highly expressed early in
development and at lower levels in the adult.9 Interestingly, the
AT2 receptor is upregulated in response to ischemia and inflam-
mation suggesting a potential role in myocardial angiogenesis.11
Previous studies have shown that the AT2 receptor may interact
with the bradykinin receptor, the B2 kinin receptor (B2), during
signaling.12
In the present study, we have investigated the mechanism of
angiogenesis in response to Ang II in an in vitro model of sprout
formation in the mouse heart under conditions of normoxia
(21% O2) and severe hypoxia (1% O2) by dissecting the role of
AT receptor subtypes and identifying the downstream effectors.
Methods
Animals
Experiments were performed with hearts of C57Bl/6 wild-type,
AT1a/ (Jackson Laboratories), and B2/ mice (Jackson Laborato-
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ries). FVB/J AT2/ mice were a gift from Prof Lutz Hein (Institut
fu¨r Experimentelle und Klinische Pharmacologie und Toxicologie,
Freiburg, Germany) and have been described previously.13 The
animals were euthanized and the hearts immediately transferred to
PBS. Within 30 minutes postmortem, small pieces (1 mm3) of the
mouse myocardium (left ventricle) were cut and embedded in fibrin
gel. All of the experiments were conducted in accordance with the
Swiss Federal Act on Animal Protection (1998) and were approved
by the Veterinary Department of the Kanton of Basel (Switzerland).
We used between 5 and 9 mice for every experiment. The age of
mice ranged from 12 to 14 weeks.
Angiogenesis In Vitro Assay
A 3D in vitro assay of heart angiogenesis was established in our
laboratory as described in detail previously.14 Briefly, 0.5- to 1-mm3
cubes from the left ventricular myocardium of the mouse heart were
placed onto fibrin gels (Sigma-Aldrich) with 500 L of DMEM plus
5% FCS (Biochrom). Heart explants were incubated under normoxia
(21% O2) or hypoxia (1% O2) for 7 days. Stimulants/inhibitors were
added every other day: hrVEGF164 (R&D systems), HOE140 (Sigma-
Aldrich AG), Ang II acetate (Sigma-Aldrich), losartan (MSD),
CGP-42112 (Bachem), PD123319 (Fluka), PKSI-527 (Wako Chem-
icals), and NO inhibitors and donors (Sigma-Aldrich).
Inhibitors were added fresh 20 minutes before stimulants. After 7
days, endothelial sprouts were photographed digitally (ColorView
II-Soft Imaging System) on an inverted light microscope (Olympus
IX50). The extent of sprout formation was determined as detailed
previously.13 Briefly, we used octuplicates for each condition, and
sprout formation was calculated and averaged by 2 independent
investigators by comparison with a standardized scale (angiogenic
index). The angiogenic index was defined with the help of an image
analysis software (AnalySIS Pro, Soft Imaging System) as [sprouting
area/total area]10, where total area corresponds with the sprouting
area plus tissue area. Sprouting was computed from the area that was
actually occupied by endothelial sprouts and not the space between the
cells. Sprouting and tissue area were computed by AnalySIS Pro, and
the angiogenic index was rounded to the nearest integer and handled as
a scored value.
Characterization of Cells and Tissue
Characterization of outgrowing cells and sprouts was performed by
using specific cell markers GSL-IB4 (20 g/mL; Rectolab) for
endothelium, Cy3-conjugated anti--smooth muscle actin (1:100;
Fluka Chemie) for smooth muscle cells/pericytes, and Hoechst dye
(Polysciences Europe) for visualization of cell nuclei as described
previously.14
NO Production Assay
NO concentrations were measured by the fluorometric nitrite assay15
with the NO Assay kit (Calbiochem). Briefly, pieces of mouse heart
were incubated in phenol-free DMEM. The supernatants were
collected, nitrite was detected by fluorescence, and concentration
(nanomoles per liter) was calculated according to a calibration curve
in each experiment.
Western Blotting
Heart tissue was lysed in radioimmunoprecipitation assay buffer as
described before.1 After SDS-PAGE, proteins were transferred onto
polyvinylidene fluoride membrane (Millipore). The membrane was
blocked with 4% skim milk powder in Tris-buffered saline–Tween
solution and probed with polyclonal anti-AT1 (N-10) and anti-AT2
(C-18) from Santa Cruz Biotechnology. Horseradish peroxidase–
conjugated IgGs from Cell Signaling Technology were used to
visualize the proteins by a chemiluminescence reaction (Amersham).
RT-PCR
Total RNA was isolated with TRIzol Reagent (Invitrogen), quanti-
fied, and reverse transcribed with a Moloney-murine leukemia virus
reverse transcriptase system (Promega).
The cDNA (1 L) was amplified in 35 cycles of PCR. The
following primer sequences were used: for mouse AT1 receptor
sense: 5-TGAGAACACCAATATCAC TG-3 and antisense: 5-
TTCGTAGACAGGCTTGAG-3; mouse AT2 receptor sense: 5-
CCTTGGCTGACTTACTCCTT-3 and antisense 5-GAACTACA-
TAAGATGCTTGCC-3; and mouse 18S ribosomal RNA sense:
5-CCTGGATACCGCAGCTAGGA-3 and antisense 5-GCGGC-
GCAATACGAATGCCCC-3. Specific PCR annealing temperatures
were 49°C for AT1, 52°C for AT2, and 57°C for 18S.
Statistical Analysis
All of the depicted results represent experiments repeated using 5
different heart explants. Each single condition was performed in
octuplicate wells. Data points represent the meanSEM. Statistical
analysis was performed with SPSS for Mac OS X (SPSS Inc).
Statistical significance (P0.05) was computed using nonparametric
analysis; Kruskal–Wallis and Mann–Whitney tests were performed
accordingly.
Results
Ang II Induces Vascular Sprouting of the Adult
Mouse Heart Under Hypoxia
We analyzed the effect of Ang II in an in vitro model of
angiogenesis of the heart14 both under normoxia (21% O2)
and hypoxia (1% O2). Under normoxia, neither Ang II nor the
angiogenic growth factor VEGF16 that was used as positive
control elicited an angiogenic response (Figure 1A and 1B) in
the mouse heart. However, under hypoxia Ang II, bradykinin
and VEGF elicited a significant angiogenic response (Figure
1A and 1B) of a similar magnitude (2.2-, 1.9-, and 2.4-fold
increase, respectively, compared with negative control
P0.05). Staining with fluorescently labeled antibodies (Fig-
ure 1C) revealed that Ang II–induced sprouts typically
consist of endothelial cells aligned with smooth muscle
cells/pericytes. Because hypoxia was confirmed to be a
prerequisite for in vitro angiogenesis of the adult mouse heart
(see also Reference 14), all of the following experiments were
performed in hypoxia.
Ang II Induces Dose-Dependent Sprouting
Through the AT2 Receptor
Stimulation of heart explants with a wide concentrations
range of Ang II (1010 to 106 mol/L) showed that endothelial
sprouting induced by Ang II was dose dependent over at least
a 1000-fold range of concentrations and was maximal at 107
mol/L (2.20.3; n5; P0.05; Figure 2).
Next, we evaluated the contribution of AT1 and AT2
receptors in Ang II–mediated sprout formation. The selective
AT2 agonist CGP-42112 induced an angiogenic response
similar to that observed in Ang II–stimulated hearts (2-fold
increase with 107 mol/L CGP-42112; P0.05 versus con-
trol; Figure 2). AT1 and AT2 receptor inhibitors corroborated
these results (Figure 3). Losartan, a specific AT1 inhibitor, did
not affect Ang II–induced sprout formation. PD 123319, a
selective AT2 antagonist, significantly reduced Ang II–in-
duced sprout formation to control levels (P0.05). The
combination of both antagonists elicited a response very
similar to that seen with PD 123319 alone (P0.05). CGP-
42112–induced sprout formation was inhibited by PD123319
but not by losartan (data not shown). Taken together, these
results suggest that the AT2 receptor subtype mediates the
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angiogenic effect induced by Ang II in the mouse heart under
hypoxia.
Ang II Does Not Induce Sprouting in
AT2/ Animals
To confirm these latter findings, we examined hearts from
AT1a/ and AT2/ mice. Ang II could not induce sprouting
above control levels in heart explants from adult AT2/ mice
under hypoxia (Figure 4), either alone or after blocking the
AT1 receptor with losartan. However, VEGF induced a
significant level of sprout formation compared with controls
(2.6-fold increase; P0.05), suggesting that VEGF-induced
angiogenesis in vitro is independent of AT2 signaling. On the
other hand, Ang II induced sprout formation in heart explants
from AT1a/ mice as efficiently as in wild-type hearts
(1.9-fold increase; P0.05; Figure 4). In these mice, Ang II
also elicited sprouting in the presence of losartan, which
inhibits both AT1a and AT1b receptors, excluding the possi-
bility that the observed angiogenic effect could be mediated
by the AT1b receptor still present in the AT1a/ mice. On the
other hand, PD 123319 completely inhibited sprout formation
(P0.05) in the AT1/ heart explants. These results clearly
demonstrate the exclusive role of the AT2 receptor in Ang
II–mediated angiogenesis in adult hypoxic mouse heart
explants.
AT1 and AT2 Receptor Expression Under Hypoxia
To exclude the possibility that AT2-dependent Ang II–
induced sprout formation could be because of the downregu-
lation of AT1 receptor in hypoxia, we determined AT1 and
AT2 receptor protein and mRNA expression in wild type
mouse heart explants. As shown in figure 5, both AT1 and
Figure 1. Ang II induces endothelial sprouts in a
heart angiogenesis assay in vitro. A, Mouse hearts
stimulated with 107 mol/L of Ang II, 107 mol/L of
bradykinin, 10 ng/mL of VEGF164, or diluent control
after 7 days in culture under 21% O2 (normoxia) or
1% O2 (hypoxia). B, Ang II (107 mol/L), bradykinin
(107 mol/L), or VEGF164 (10 ng/mL) increased
sprouting only under hypoxia. A standardized scale
indicates the degree of cellular outgrowth (angio-
genic index). Data points represent the mean of 5
independent experimentsSEM. C, Fixed Ang
II–induced sprout stained for endothelial cells by
fluorescein-conjugated GSL-IB4 (green), for pericytes
or smooth muscle cells by Cy3-conjugated -smooth
muscle actin (red), and for nuclei by Hoechst-dye
(blue).
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AT2 were expressed confirming that both pathways are
available for signaling.
Ang II Induces Sprouting via an AT2–B2
Receptor Pathway
To analyze the role of the B2 receptor, we stimulated hypoxic
mouse heart explants with Ang II in both wild-type and
AT1/ animals in the presence of HOE 140, a selective B2
antagonist (Figure 6A). We found an Ang II–induced angio-
genic response (wild-type: 3.5 fold increase; AT1/: 3.3-fold
increase versus control; P0.05) that was completely abol-
ished by HOE 140 (P0.05). Bradykinin, per se (107
mol/L), induced sprout formation both in wild-type and
AT2/ mouse hearts (wild-type: 1.44-fold increase; AT2/:
1.5-fold increase versus control; P0.001). To confirm that
Ang II–induced angiogenesis requires the B2 receptor, heart
explants from B2/ mice were assessed. Neither Ang II nor
VEGF induced significant sprouting in B2/ mice (Figure
6B). To clarify whether accumulation of bradykinin was the
intermediate step in Ang II–induced sprouting, we treated the
heart explants with a specific kininogenase inhibitor, PKSI-
527 (105 mol/L), that blocks the conversion of kinins into
bradykinin. PKSI-527 completely inhibited Ang II–induced
angiogenesis in the wild-type mouse heart (Figure 6C).
Therefore, we conclude that Ang II is angiogenic in the
mouse heart under hypoxia via a pathway involving both the
AT2 and the B2 receptors linked by activation of bradykinin
production.
Ang II–Induced Sprouting Requires NO Release
Because stimulation of the AT2 receptor is associated with
increased generation of bradykinin,17 NO, and cGMP18, we
tested whether the angiogenic effects of Ang II may also
require NO. As expected, Ang II (107 mol/L) and bradykinin
(107 mol/L) significantly increased NO production as mea-
sured by nitrite accumulation in the medium after 7 days of
incubation (in 109 mol/L, control: 905; bradykinin:
1215; Ang II: 11415; n3; P0.05; ANOVA). We then
inhibited NO generation using NO synthase inhibitors, that is,
s-Methylisothiourea, L-N5-(1-iminoethyl)-ornithine, NG-
nitro-L-arginine methyl ester, and N-(3-aminomethyl)benzyl
acetamidine. Ang II- and CGP-42112–induced angiogenesis
were completely blunted by NO inhibition (Figure 7A). Heart
explants derived from wild-type, AT2/, and BK2/ mice
were then incubated with 2 different NO donors,
Figure 2. Ang II induces dose-dependent
sprouting in vitro in adult mouse hearts in
hypoxia. Pieces of mouse heart were
stimulated with Ang II from 1010 to 106
mol/L (left) or AT2 agonist CGP-42112
from 109 to 106 mol/L (right) and incu-
bated under hypoxia for 7 days. Data
points represent the mean of 5 indepen-
dent experiments  SEM.*P0.05 vs
negative control.
Figure 3. AT1 is not required for Ang II–induced sprouting.
Pieces of mouse heart were incubated with Ang II (107 mol/L)
alone or in combination with losartan (106 mol/L) and/or PD
123319 (106 mol/L) under hypoxia for 7 days. The AT2 inhibitor
(PD123319) but not the AT1 blocker losartan significantly
decreases Ang II–mediated sprout formation. Data points repre-
sent the mean of 5 independent experimentsSEM. *P0.05 vs
negative control.
Figure 4. Ang II–induced angiogenesis is impaired in hearts
from AT2/ but not from AT1/ mouse. Pieces of mouse heart
from AT2/ (left side of the figure) and AT1/ mice (right side of
the figure) were stimulated with Ang II (107 mol/L) alone or in
combination with losartan (106 mol/L) or PD 123319 (106
mol/L) and incubated under hypoxia for 7 days. VEGF164 (10
ng/mL) was used as a positive control. Data points represent
the mean of 5 independent experiments  SEM. *P0.05 vs
VEGF (left) and *P0.05 vs negative control (right).
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S-nitrosoglutathione (105 mol/L) and PAPA NONOate (105
mol/L; Figure 7B). Both NO donors induced angiogenesis
(S-nitrosoglutathione; wild-type: 1.7-fold increase; AT2/:
1.7-fold increase; BK2/: 1.6-fold increase versus control;
P0.05). These results demonstrate that NO is a key medi-
ator of angiogenesis in the hypoxic mouse heart and is a
required downstream effector of Ang II–induced sprout
formation.
Discussion
Here we show that Ang II induces angiogenesis in the adult
mouse heart specifically under hypoxia, signaling through the
AT2 but not the AT1 receptor. The mechanism requires
generation of bradykinin with activation of the B2 receptor
and leads to NO biosynthesis as the downstream effector.
The renin–angiotensin-aldosterone system is an important
system in regulating vascular homeostasis. However, the
precise role of the renin–angiotensin-aldosterone system and
the AT1/AT2 receptor pathway in angiogenesis is unclear.
Clinical data have shown that blocking the AT1 receptor
preserves cardiac function after myocardial infarction.19 Our
results showing that Ang II–induced angiogenesis in the
mouse heart under hypoxia is mediated exclusively by the
AT2 receptor may explain some beneficial effects of AT1
blockade treatment in the heart. In fact, AT1 blockade may
unmask beneficial properties because of preferential AT2
stimulation.
The role of the AT1 and AT2 receptor in angiogenesis is
controversial. Ang II–induced angiogenesis was shown to be
mediated via both the AT1 and the AT2 receptor in the
mesenteric vasculature of Ang II–infused rats20 or specifi-
cally via the AT2 receptor in tumor angiogenesis in mice.21
High AT1 expression was associated with reduced myocardial
vessel density in rats.22 In contrast, others have shown
AT1–dependent angiogenesis in the ischemic hind limb of
mice,23 whereas AT2 appeared to be antiangiogenic in the
same animal model.24 Tumor angiogenesis was impaired in
AT1/ receptor mice.25 Thus, the role of AT1 and AT2
receptors in angiogenesis is not clear and may vary on model,
tissue, and conditions investigated. In particular, the vascu-
lature of the heart has not been investigated in models of
controlled hypoxia. Our model of angiogenesis in vitro of the
mouse heart provides this possibility and demonstrates the
key role of hypoxia in Ang II–induced cardiac angiogenesis.
Hypoxia can lead to the formation of new vessels in mature
tissue, triggering vessel growth by signaling through hypox-
ia-inducible transcription factor-1.26 Interestingly, Ang II
induces hypoxia-inducible transcription factor-1.27–29 Hyp-
oxia may also modulate the expression of AT1 and/or AT2
receptors.30 In our experiments, both AT1 and AT2 receptors
were present under normoxia and hypoxia. Still, further
studies investigating other tissues, receptor expression, and
intracellular signaling pathways may reveal whether AT2-
dependent angiogenesis is specific for the hypoxic heart.
The AT2 receptor might exert downstream effects via the
B2 receptor.12 We clearly show that Ang II–induced angio-
genesis is abrogated when the B2 receptor is pharmacologi-
cally inhibited or knocked out. B2 activation by bradykinin
Figure 5. AT1 and AT2 mRNA and protein expression of the
mouse heart in vitro under hypoxia. Pieces of heart from wild-
type mice were incubated under 21% O2 or 1% O2 during 24
hours, lysed, and protein and mRNA extracted. Western blotting
and RT-PCR analysis show that both the AT1 and the AT2
receptor are expressed under normoxia and hypoxia.
Figure 6. Ang II–induced sprouting in wild-type and AT1 knockout mice requires the B2 receptor. A, Pieces of heart from wild-type or
AT1/ mice stimulated with Ang II (107 mol/L) alone or in combination with the specific B2 receptor antagonist HOE 140 (107 mol/L)
and incubated under hypoxia during 7 days. HOE 140 significantly (*P0.05 vs negative control) decreased Ang II–induced sprout for-
mation in wild-type and AT1/ mice compared with Ang II–treated heart pieces without the inhibitor. B, Pieces of hearts from B2/
mice stimulated with Ang II (107 mol/L) alone or in combination with PD123319 (106 mol/L) were incubated in culture medium con-
taining 5% FCS under hypoxia for 7 days. VEGF164 (10 ng/mL) was used as a positive control. *P value not significant. Data points rep-
resent the mean of 5 independent experimentsSEM. C, Pieces of heart from wild-type mice were stimulated with Ang II (107 mol/L)
alone or in combination with kininogenase-specific inhibitor PKSI-527 (105 mol/L) were incubated in culture medium containing 5%
FCS under hypoxia for 7 days. VEGF164 (10 ng/mL) was used as a positive control. Data points represent the mean of 3 independent
experiments  SEM. *P0.05 vs control.
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induces vasodilation,31 which is also a prerequisite for initi-
ation of angiogenesis.32 AT2-overexpressing mice blocked
Ang II–induced vasopressor effects through the B2 recep-
tor.33 Importantly, bradykinin was shown to induce angiogen-
esis via the B2 receptor34 or as shown by using a model of
ischemia induced in hind limbs in B2/ mice.35 Collectively,
these data suggest a mechanism by which a vasopressor
molecule, such as Ang II, can also mediate vasodilator and
angiogenic effects specifically by AT2 receptor–dependent
signaling leading to B2 kinin receptor activation.36 Ang
II–dependent activation of B2 could be achieved in different
ways. A direct interaction between AT2 and B2 leading to NO
production has been described recently,37 although the precise
nature of this interaction has not been fully clarified. Others
have pointed out an Ang II–mediated pH increase that may
release kininogens to produce bradykinin.33,38 In our study,
the angiogenic effect of B2 receptor depended on bradykinin
synthesis, because kininogenase inhibition blocked Ang II–
induced angiogenesis. Bradykinin induced angiogenesis in
hypoxic heart explants only from both wild-type and AT2/
mice. Ang II, however, as mentioned before, failed to induce
angiogenesis in hearts from BK2/ mice. We conclude that
angiogenesis induced by Ang II requires signaling through
the AT2 receptor and is mediated by an increase in bradykinin
production.
Endothelium-derived NO synthase is crucial for angiogen-
esis in vitro and in vivo.39 In fact, NO inhibition blocked Ang
II–induced endothelial sprout formation in our model of
angiogenesis of the heart in vitro. Increased nitrite accumu-
lation in the medium of Ang II–stimulated heart explants was
also observed. Accordingly, NO donors directly induced
angiogenesis in pieces of heart from wild-type, B2/, and
AT2/ mice. Our results are in agreement with previous
reports, showing that Ang II can induce renal production of
bradykinin, NO, and cGMP via the AT2 receptor.40 These
data suggest that an increase in NO bioavailability down-
stream of AT2 and B2 receptors is the final effector of Ang
II–induced angiogenesis in the hypoxic heart.
Perspectives
The present study provides evidence for the significant role of
the AT2/B2 pathway in the Ang II–induced angiogenesis in
vitro in the adult mouse heart under hypoxia. In clinical
studies, AT1 blocker treatment of hypertension has revealed
additional cardioprotective effects beyond the lowering blood
pressure.41,42 A potential advantage of AT1 blockers over
Figure 7. NO mediates Ang II–induced
sprouting under hypoxia. A, Pieces of
heart from wild-type mice stimulated with
Ang II (107 mol/L; left) or with the AT2
agonist (CGP-42112, 107 mol/L; right)
alone or in the presence of different NO
synthase inhibitors (107 mol/L) and incu-
bated in culture medium containing 5%
FCS under hypoxia for 7 days. *P0.05 vs
control. Data points represent the mean
of 5 independent experimentsSEM.
B, Pieces of heart from wild-type, AT2/,
and B2/ mice were stimulated with two
different NO donors: S-nitrosoglutathione
(GSNO) (105 mol/L) and PAPA NONOate
(105 mol/L) and incubated in culture
medium containing 5% FCS under hypoxia
for 7 days. *P0.05 vs control. Data points
represent the mean of 5 independent
experimentsSEM.
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angiotensin-converting enzyme inhibition is the preservation of
the AT2-mediated pathway. Here we describe that Ang II–
induced angiogenic effects through AT2/B2 may provide some
explanation for these beneficial effects. Studies on neovascular-
ization of the heart in hypertensive animals and patients after
AT1 treatment are needed to test the clinical relevance of our
mechanistic results. This may help us to understand and to
uncover novel therapeutic effects of AT1 receptor blockers for
patients with left ventricular hypertrophy, ischemic heart dis-
ease, or myocardial infarction.
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